Neurogene (NGNE) Liabilities and Shareholders Equity (2013 - 2026)

Neurogene (NGNE) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $263.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 16.54% year-over-year to $263.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 14.26% YoY) and the FY2025 annual result came in at $288.6 million, down 14.04% from the prior year.
• Liabilities and Shareholders Equity fell to $263.1 million in Q1 2026, from $288.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $335.7 million in Q4 2024 to a low of $89.6 million in Q3 2023.
• A 5-year average of $197.3 million and a median of $179.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 103.7% in 2023, down 33.98% in 2023.
• Tracing NGNE's Liabilities and Shareholders Equity over 5 years: stood at $109.3 million in 2022, then jumped by 103.7% to $222.6 million in 2023, then soared by 50.84% to $335.7 million in 2024, then slipped by 14.04% to $288.6 million in 2025, then dropped by 8.82% to $263.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $263.1 million (Q1 2026), $288.6 million (Q4 2025), and $287.8 million (Q3 2025), per Business Quant data.